SCHEMBL19682925

SCHEMBL19682925

COC(=O)c1cc(Cl)cnc1S(=O)(=O)Cl

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 4/20 0.44
LMNA P02545 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CHRM2 P08172 1/20 0.42
CHRM1 P11229 1/20 0.42
RRM1 P23921 1/20 0.42
RRM2B Q7LG56 1/20 0.42
ABL1 P00519 1/20 0.41
NR4A2 P43354 2/20 0.40
ALDH1A1 P00352 2/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
MAPK1 P28482 1/20 0.39
SERPINH1 P50454 1/20 0.38
KDM4E B2RXH2 1/20 0.37
GAA P10253 2/20 0.37
RXFP1 Q9HBX9 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19682732 0.83 OPRK1 (0.46) OPRK1CHRM2CHRM1RRM1RRM2B
SCHEMBL30816026 0.80 OPRK1 (0.48) OPRK1L3MBTL1ABL1NR4A2ALDH1A1
SCHEMBL473981 0.80 OPRK1 (0.48) OPRK1L3MBTL1ABL1NR4A2ALDH1A1
SCHEMBL401530 0.78 OPRK1 (0.47) OPRK1L3MBTL1ABL1NR4A2ALDH1A1
SCHEMBL21462378 0.77 OPRK1 (0.46) OPRK1ABL1NR4A2ALDH1A1SLC6A4
SCHEMBL914850 0.77 ABL1 (0.51) OPRK1ABL1NR4A2ALDH1A1SLC6A4
SCHEMBL10473574 0.77 OPRK1 (0.46) OPRK1LMNAABL1NR4A2ALDH1A1
SCHEMBL19682934 0.77 KDR (0.49) OPRK1LMNAABL1NR4A2ALDH1A1
SCHEMBL29733564 0.77 ABL1 (0.51) OPRK1ABL1NR4A2ALDH1A1SLC6A4
SCHEMBL25359268 0.75 OPRK1 (0.45) OPRK1L3MBTL1ABL1NR4A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3466934-B1 SULFONAMIDE COMPOUNDS OR SALT THEREOF AS RIBONUCLEOTIDE REDUCTASE INHIBITORS FOR TREATING CANCER TAIHO PHARMACEUTICAL CO LTD (JP) 2024-03-27 EP disclosed
US-11634395-B2 Sulfonamide compound or salt thereof Taiho Pharmaceutial Co., Ltd. (JP) 2023-04-25 US disclosed
CN-109563057-B Sulfonamide compound or salt thereof 大鹏药品工业株式会社 2022-06-24 CN disclosed
US-10889555-B2 Sulfonamide compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-01-12 US disclosed
US-10889555-B2 Sulfonamide compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-01-12 US disclosed
US-20200405697-A1 Antitumor Agent TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-31 US disclosed
US-20200405697-A1 Antitumor Agent TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-31 US disclosed
US-20200399235-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-24 US disclosed
US-20200399235-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-24 US disclosed
EP-3718545-A1 ANTITUMOR AGENT Taiho Pharmaceutical Co., Ltd. (JP) 2020-10-07 EP disclosed
EP-3718545-A1 ANTITUMOR AGENT Taiho Pharmaceutical Co., Ltd. (JP) 2020-10-07 EP disclosed
US-20200157066-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-05-21 US disclosed
US-20200157066-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-05-21 US disclosed
EP-3466934-A1 SULFONAMIDE COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2019-04-10 EP disclosed
EP-3466934-A1 SULFONAMIDE COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2019-04-10 EP disclosed
WO-2017209155-A1 SULFONAMIDE COMPOUND OR SALT THEREOF 大鵬薬品工業株式会社 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399235-A1 Sulfonamide Compound or Salt Thereof RNASEH1, SNRPA1, RRM2 OPRK1 2566/4885LMNA 3354/4885L3MBTL1 2379/4885
US-20200157066-A1 Sulfonamide Compound or Salt Thereof RNASEH1, SNRPA1, RRM2 OPRK1 2566/4885LMNA 3354/4885L3MBTL1 2379/4885
US-10889555-B2 Sulfonamide compound or salt thereof RNASEH1, SNRPA1, RRM2 OPRK1 2566/4885LMNA 3354/4885L3MBTL1 2379/4885
US-11634395-B2 Sulfonamide compound or salt thereof RNASEH1, SNRPA1, RRM2 OPRK1 2566/4885LMNA 3354/4885L3MBTL1 2379/4885
US-20200405697-A1 Antitumor Agent HNRNPR, RRM2, RRM2B OPRK1 2247/4885LMNA 3925/4885L3MBTL1 1769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.